Emergent BioSolutions files $86M IPO
Gaithersburg, MD-based Emergent BioSolutions has filed an $86 million IPO with the SEC. Emergent didn't say how shares would be offered or the price range of the shares. The company ,which manufactures immunobiotics, operates both a biodefense and commercial business and its lead product candidate is BioThrax, an anthrax vaccine.
- here's the AP report on the offering
ALSO: Lexington, MA-based ActivBiotics plans to pursue an IPO worth up to $46 million. The company's lead drug Rifalazil is in Phase III testing for the symptoms of peripheral arterial disease. It's also in Phase II trials for arterosclerosis. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
